Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Olutasidenib (Primary)
  • Indications Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Glioblastoma; Glioma; Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors FORMA Therapeutics; Novo Nordisk

    • Most Recent Events

    • 05 Jan 2023 Results (n=26) assessing the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation, published in the Neuro-Oncology.
    • 25 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2022 Planned End Date changed from 1 Apr 2022 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top